Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Idecabtagene vicleucel for R/R myeloma

Jesús San Miguel • 22 Jun 2020
EHA 2020
Multiple Myeloma CAR-T Idecabtagene vicleucel
KarMMa

Jesus San Miguel, MD, of the University of Navarra, Navarra, Spain, updates us on the KarMMa study (NCT03361748), which investigated the BCMA-targeted CAR-T cell therapy, idecabtagene vicleucel, in relapsed or refractory (R/R) multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jesús San Miguel

PRO and safety in patients with NDMM achieving MRD negativity in the PERSEUS and CEPHEUS trials 4:12
PRO and safety in patients with NDMM achieving MRD negativity in the PERSEUS and CEPHEUS trials
Jesús San Miguel • 9 Sep 2025
Updated findings from GEM2017FIT: triplet versus quadruplet regimen in NDMM 4:56
Updated findings from GEM2017FIT: triplet versus quadruplet regimen in NDMM
Jesús San Miguel • 9 Sep 2025
Approaching patients with myeloma who progress on lenalidomide & daratumumab: challenges 2:04
Approaching patients with myeloma who progress on lenalidomide & daratumumab: challenges
Jesús San Miguel • 19 Sep 2024
CARTITUDE-4: how is CAR-T opening new avenues for the treatment of R/R myeloma? 1:28
CARTITUDE-4: how is CAR-T opening new avenues for the treatment of R/R myeloma?
Jesús San Miguel • 19 Sep 2024

Related Videos

The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma 4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry 1:29
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry
Karthik Ramasamy • 7 Dec 2025
The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3 2:33
The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3
Faith Davies • 7 Dec 2025
Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL 2:30
Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL
James Berenson • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals